{
    "organizations": [],
    "uuid": "8fb66d01217926caa5324e39954f50af5762609d",
    "author": "Reuters Editorial",
    "url": "https://www.reuters.com/article/brief-theranexus-announces-first-europea/brief-theranexus-announces-first-european-authorization-for-clinical-study-of-phase-2-with-thn-102-in-parkinsons-disease-idUSFWN1RW0U5",
    "ord_in_thread": 0,
    "title": "BRIEF-Theranexus Announces First European Authorization For Clinical Study Of Phase 2 With Thn 102 In Parkinson's Disease",
    "locations": [],
    "highlightText": "",
    "language": "english",
    "persons": [],
    "text": "April 19 (Reuters) - THERANEXUS SA:\n* ANNOUNCES FIRST EUROPEAN AUTHORIZATION FOR CLINICAL STUDY OF PHASE 2 WITH THN 102 IN PARKINSONâ€™S DISEASE\n* FIRST GREEN LIGHT FOR LAUNCH OF MULTICENTRIC INTERNATIONAL STUDY PHASE 2 Source text : bit.ly/2EXTIJP Further company coverage: (Gdynia Newsroom)\n ",
    "published": "2018-04-20T00:12:00.000+03:00",
    "crawled": "2018-04-20T11:36:03.002+03:00",
    "highlightTitle": "",
    "preprocessed_text": [
        "april",
        "reuters",
        "theranexus",
        "sa",
        "announces",
        "first",
        "european",
        "authorization",
        "clinical",
        "study",
        "phase",
        "thn",
        "parkinson",
        "disease",
        "first",
        "green",
        "light",
        "launch",
        "multicentric",
        "international",
        "study",
        "phase",
        "source",
        "text",
        "company",
        "coverage",
        "gdynia",
        "newsroom"
    ]
}